Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Boyd

Pulmonary Disease Charlottesville, VA Medical Doctor

NPI 1487839270 CMS profile 67378

5 Hospital Dr, Charlottesville, VA 22908

Open in the dashboard

General payments

$4,647

351 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Boyd of Charlottesville, VA is reported in the CMS Open Payments database as having received $4,647 across 351 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51 2
2022 General $1,070 74
2021 General $1,220 94
2020 General $1,074 76
2019 General $1,232 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Boyd
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Michael Boyd were reported at $51. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Michael Boyd Pulmonary Disease median Middle half National median
2019 $1,232 $377 $109–$1,340 $163
2020 $1,074 $230 $56–$907 $114
2021 $1,220 $269 $68–$1,072 $132
2022 $1,070 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $51 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,064 122 payments
  2. AstraZeneca Pharmaceuticals LP $751 43 payments
  3. Mylan Specialty L.P. $380 18 payments
  4. United Therapeutics Corporation $325 29 payments
  5. Sunovion Pharmaceuticals Inc. $278 25 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $194 12 payments
  7. Philips Electronics North America Corporation $177 10 payments
  8. Mallinckrodt Enterprises LLC $171 9 payments
  9. Mallinckrodt Hospital Products Inc. $164 10 payments
  10. Genzyme Corporation $143 9 payments
  11. Other $998 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,518 331 payments
  2. Education $129 20 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $567 79 payments
  2. ORENITRAM $297 25 payments
  3. LONHALA MAGNAIR $278 25 payments
  4. NUCALA $274 18 payments
  5. YUPELRI $259 12 payments
  6. FASENRA $253 10 payments
  7. BREZTRI $250 16 payments
  8. DUPIXENT $205 11 payments
  9. ACTHAR Autoimmune And Rare Disease $171 9 payments
  10. ACTHAR Immunology $164 10 payments
  11. Other $3,092 199 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$71,600

Medicare's payments for the services billed

Medicare patients

211

Average age 75

Services billed

562

100 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 57%
Atrial fibrillation 53%
Heart failure 52%
Chronic kidney disease 52%
Ischemic heart disease 51%
Arthritis 50%
Depression 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

351 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record